Two of the investors behind RespiVert Ltd., which was acquired by Johnson & Johnson subsidiary Janssen Biotech, Inc. (formerly Centocor Ortho Biotech Inc.) last year are hoping to repeat the success with a sequel. Imperial Innovations Group plc and SV Life Sciences are committing up to £8 million (US$12.5 million) to TopiVert Ltd., a new start-up focused on the discovery of topical kinase inhibitors for inflammatory conditions of the eye and gut.